Insider · CIK 0001794284
Kathleen D. Scott
Files at SPRY (ARS Pharmaceuticals, Inc.), NKGN (NKGen Biotech, Inc.), DRMA (Dermata Therapeutics, Inc.). First filing Oct 17, 2024, latest May 22, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRY: ARS Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | ARS Pharmaceuticals, Inc. | $705k 50,000 shares | -87% | +41% from low-18% from high | |
| 34Weak | ARS Pharmaceuticals, Inc. | $200k 12,500 shares | -72% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock | +50,000 | $1.50 | $75k | 57,424 | May 22, 2025 |
| May 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -50,000 | $14.10 | $705k | 7,424 | May 22, 2025 |
| May 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 752,330 | May 22, 2025 |
| Jan 13, 2025 | DRMA Dermata Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 14, 2025 |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | AGrant or award Stock option (right to buy)derivative | +176,700 | $0.00 | $0 | 176,700 | Jan 3, 2025 |
| Dec 6, 2024 | NKGN NKGen Biotech, Inc. | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 10, 2024 |
| Dec 6, 2024 | NKGN NKGen Biotech, Inc. | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Dec 10, 2024 |
| Oct 16, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +12,500 | $1.50 | $19k | 17,449 | Oct 17, 2024 |
| Oct 16, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -12,500 | $16.00 | $200k | 4,949 | Oct 17, 2024 |
| Oct 16, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,500 | $0.00 | $0 | 802,330 | Oct 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.